The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection by White, L. J. et al.
  
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
 
Author(s): L. J. WHITE, M. WARIS, P. A. CANE, D. J. NOKES and G. F. 
MEDLEY  
Article Title: The transmission dynamics of groups A and B human 
respiratory syncytial virus (hRSV) in England & Wales and Finland: 
seasonality and cross-protection 
Year of publication: 2005 
Link to published 
version: http://dx.doi.org/10.1017/S0950268804003450  
Publisher statement: None 
 
 
The transmission dynamics of groups A and B human
respiratory syncytial virus (hRSV) in England & Wales
and Finland: seasonality and cross-protection
L. J. WHITE1,4*, M. WARIS2, P. A. CANE3, D. J. NOKES1,4 AND G. F. MEDLEY1
1 Ecology & Epidemiology Group, University of Warwick, Coventry, UK
2 Department of Virology, University of Turku, Turku, Finland
3 Health Protection Agency Antiviral Susceptibility Reference Unit, University of Birmingham Medical School,
Birmingham, UK
4 Centre for Geographic Medicine Research – Coast, Kenya Medical Research Institute, Kiliﬁ, Kenya
(Accepted 1 November 2004)
SUMMARY
Human respiratory syncytial virus (hRSV) transmission dynamics are inherently cyclical, and the
observed genetic diversity (between groups A and B) also appears to have a repeating pattern. A
key unknown is the extent to which genetic variants interact immunologically, and thus impact
on epidemiology. We developed a novel mathematical model for hRSV transmission including
seasonal forcing of incidence and temporary intra- and inter-group partial immunity.
Simultaneous model ﬁts to data from two locations (England & Wales, UK, and Turku, Finland)
successfully reproduced the contrasting infection dynamics and group A/B dominance patterns.
Parameter estimates are consistent with direct estimates. Diﬀerences in the magnitude and
seasonal variation in contact rate between the two populations alone could account for the
variation in dynamics between these populations. The A/B group dominance patterns are
explained by reductions in susceptibility to and infectiousness of secondary homologous and
heterologous infections. The consequences of the observed dynamic complexity are discussed.
INTRODUCTION
Respiratory syncytial virus infection in humans
(hRSV) is ubiquitous, the major viral cause of severe
acute respiratory infection in childhood worldwide,
and estimated to be responsible for 160 000 deaths per
year [1]. The virus exhibits considerable genetic
variability, primarily in the attachment (G) glyco-
protein [2]. This variability is reﬂected antigenically,
and hRSV can be divided into two groups (A and B)
on the basis of reactions with panels of monoclonal
antibodies [3, 4]. Children usually experience their
ﬁrst infection before the age of 2 years, and re-
infection is a common occurrence in older children
and also in adults [5–9]. Disease resulting from infec-
tion occurs principally in young children, particularly
following primary infection [5, 10, 11] but is also
observed in vulnerable adults. The reduced severity,
with increasing age, is presumably in part a result of
developing immunity to disease, but also in part
physiological, i.e. older children have larger airways
[12]. Clearly immunity is not necessarily protective
against re-infection, but it is unclear to what extent
immunity to disease or re-infection is group speciﬁc
[2, 13].
The epidemiology of hRSV disease is characterized
by marked seasonal patterns. In the United Kingdom,
the annual epidemic peaks between late December
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and early January, and a cyclic, triennial pattern in
genetic variation in groups A and B has been observed
in Birmingham, UK [2, 14]. The transmission of
hRSV in Turku, Finland has followed a distinctive
quadrennial pattern for the past 20 years [15] : every
2 years there is a minor peak in April followed by
a major peak in December. The group dominance
alternates every 2 years. These observations taken
together suggest that there is a potentially complex
relationship between viral genetic variation, infection/
disease and transmission dynamics. The consistency
of the patterns is suggestive of an underlying mech-
anism that we attempt to understand better.
The characteristic recurrent epidemics of hRSV
are, on the whole, observed through hospital surveil-
lance, with cases consisting predominantly of young
children experiencing severe disease from their pri-
mary infection [2]. Epidemics have been recorded in
community and family study settings, and the link
between elder school siblings and primary infant cases
is strong [6, 16, 17]. However, the exact role of re-
infection in the maintenance of hRSV transmission
in communities, and hence the relationship between
(observed) epidemics of primary infections and (un-
observed) seasonal epidemics of re-infection in the
general population is not clear.
The fact that, globally, the observed period of
hRSV epidemic behaviour is a natural number (i.e.
positive integer) suggests annual forcing. That is,
having taken account of the number of infectious
individuals, the remaining component of the risk of
infection would vary throughout the year based on
annually varying factors. The alternative explanation
would be that transmission dynamics (created by
interplay between susceptibility and infection) have
sustained oscillations of period n years. However,
sustained oscillations are rarely obtained from epi-
demiological models without seasonal forcing [18].
Models including the interaction between strains (i.e.
cross-immunity between types) can produce sustained
oscillations [19, 20] with the frequency of the oscil-
lations deﬁned by the parameters of the model. It is
highly unlikely that these values would combine to
give a period of precisely n years (n being a natural
number), especially where n varies between regions.
Previous epidemiological models including seasonal
forcing have reproduced observed hRSV dynamics
[21] for both regular and irregular general periodic
behaviour [18]. Models have also been used to
consider the interaction between multiple strains or
species and its eﬀect on the behaviour of the whole
biological system [22, 23]. We consider a model with
seasonal forcing as implemented previously [21],
but extended to include groups A and B and their
inﬂuence on each other via re-infection and cross-
immunity.
As far as we are aware, this is a ﬁrst attempt to ﬁt a
seasonally forced, multiple strain model to speciﬁc
data. We do so with the objectives of understanding
the roles of interaction and transmission seasonality
in determining the observed epidemics of disease, and
developing hypotheses for further study.
Model structure
A schematic representation of the deterministic com-
partmental mathematical model or the transmission
of the two groups A and B structure is shown in
Figure 1, and written as a set of diﬀerential equations:
_X=mx(lA+lB+m)X+v(XA+XB)
_Pi=liXx(n+m)Pi
_Xi=n(Pi+Yi)x(sholi+shelj+v+m)Xi
+vXAB
_Pji=sheliXjx(n+m)Pji
_Yi=sholiXix(n+m)Yi
_XAB=n(Pij+Pji+Yij+Yji)
x(shesho(lA+lB)+2v+m)XAB
_Yji=shesholiXABx(n+m)Yji
li=bi(Pi+g(Pji+Yi+Yji))
bA=bA(a cos (2p(txw))+1)
bB=rbA
(i, j) 2 {(A, B), (B,A)}
9>>>>>>>>>>=
>>>>>>>>>>;
(1)
The symbol i is used to represent the groups A and B,
and where i and j occur in the same equation they
represent the two diﬀerent groups. Tables 1 and 2
summarize the deﬁnitions of the variables and par-
ameters respectively of the system.
The model describes infection and re-infection of
the two main groups (or subtypes) of RSV, A and B,
with duration of subsequent infection equal to dur-
ation of primary infection. The role of maternal anti-
bodies in the transmission of hRSV at the population
level is uncertain. It has been shown that higher levels
of maternal antibodies are associated with increased
protection from clinical infection [24], but this as-
sociation is partial and probably short term (maternal
antibodies are only present for 3–6 months [25]). For
the purposes of the model presented, it is assumed
that maternal antibodies have negligible eﬀect on
the transmission of the virus in the whole population.
To keep the population size constant, children are
born into the susceptible class, X at a rate equal to the
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inverse of the average life expectancy for the popu-
lation. They are then susceptible to a primary infec-
tion with group A or B hRSV. If infected they enter
the primary infected class, e.g. PA, and recover at rate
n into a class of individuals previously infected with
one group, e.g. XA. The duration of infection is ﬁxed
(i.e. not estimated) at 9 days [21].
Susceptible individuals who have experienced a
primary infection may be re-infected with the same
group (e.g. entry into class YA) or undergo a primary
infection with the alternative group (e.g. entry into
class PBA). If the individual is re-infected with the
same group, when they recover they re-enter the class
of those previously infected with one group, e.g. XA.
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A AB
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AB
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BA
B
B
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Y P P Y
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Fig. 1. The transmission model structure as deﬁned in eqn (1) and Tables 1 and 2. The underlying single group model is
dashed (see text). The boxes represent the state variables and the arrows represent the transitions between the states, labelled
as : Trans=transmission ; Rec=loss of infection (recovery) ; Loss=loss of immunity.
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If the individual is infected with the alternative group,
when they recover they enter the class of individuals
previously infected with both groups, XAB, where they
are susceptible to re-infections with either group.
Individuals in the classes XA and XB are subject
to proportionally altered forces of infection from
homologous (proportion sho) and heterologous (pro-
portion she) viruses. This partial immunity is also
temporary since we assume that this eﬀect lasts on
average for the inverse of the rate v, i.e. the rate of
waning speciﬁc and cross-reacting immunity is equal
and group independent. A similar situation exists for
those individuals in class XAB: since they have ex-
perienced both groups they are subject to a reduced
force of infection by the proportion shesho and lose
the immunity of previous infection by each group
independently at the rate v (i.e. the total rate of loss
of immunity is 2v). Finally, individuals undergoing
Table 1. Model variables
Variable Deﬁnition
X Proportion of hosts uninfected with no previous hRSV infection
XA Proportion of hosts uninfected with a previous infection with group A
XB Proportion of hosts uninfected with a previous infection with group B
XAB Proportion of hosts uninfected with previous infections with both groups A and B
(order not considered)
PA Proportion of hosts infected with group A and no previous infection
PB Proportion of hosts infected with group B and no previous infection
PBA Proportion of hosts infected with group A and a previous infection with group B
PAB Proportion of hosts infected with group B and a previous infection with group A
YA Proportion of hosts infected with group A and a previous infection with group A
YB Proportion of hosts infected with group B and a previous infection with group B
YBA Proportion of hosts infected with group A and previous infections with groups A and B
YAB Proportion of hosts infected with group B and previous infections with groups A and B
lA Force of infection of group A acting on naive hosts
lB Force of infection of group B acting on naive hosts
bA Seasonally varying transmission coeﬃcient for group A
bB Seasonally varying transmission coeﬃcient for group B
Table 2. Model parameters
Parameter Deﬁnition Location Estimate
Global parameters (ﬁxed between locations)
r Group B average transmission coeﬃcient relative to bA 0.9159
g Altered infectiousness factor 0.4126
sho Altered susceptibility to homologous secondary infection 0.3569
shet Altered susceptibility to heterologous secondary infection 0.8426
n Recovery rate* 40.56 yrx1
v Rate of loss of partial immunity 0.51 yrx1
Local parameters (variable between locations)
bA Group A average transmission coeﬃcient E&W 113.99 capita
x1 yrx1
Finland 99.51 capitax1 yrx1
m Birth rate* E&W 0.014 yrx1
Finland 0.012 yrx1
w Point in the year of peak transmission coeﬃcient E&W 0.929
Finland 0.97
a Amplitude of transmission coeﬃcient E&W 0.815
Finland 0.347
sf Scaling factor# E&W 397.3
Finland 6.638
* Not estimated from the model ﬁt but from another source (see text).
# Restricted to within limits (see text).
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re-infection, e.g. YA, PAB and YAB, have a uniformly
modiﬁed (lower) infectiousness, by factor g.
In summary, the model includes four aspects of
immunity: altered susceptibility to homologous in-
fections (infections of the same group as previous
infection) ; altered susceptibility to heterologous
infections (infections of the diﬀerent group from pre-
vious infection) ; altered infectiousness of secondary
infection with the virus (not group speciﬁc) ; waning
of the previous three eﬀects. It should be noted
that the model describes what is in eﬀect a ‘memory’
of past infections that, in time, wanes. As such,
individuals can re-enter the susceptible class, X, in
which all ‘memory’ of past exposures has been lost,
and can again experience a ‘primary’ infection.
The group-speciﬁc force of infection, li, is depen-
dent on the proportions of individuals infected, with
primary infected individuals (PA and PB) making
a higher contribution than those undergoing re-
infections (YA, YB, PAB, PBA, YAB and YBA) as deter-
mined by parameter g. The force of infection is also
dependent upon some measure of the potential for
transmission that is dependent upon time, and is
captured in the term, b. This transmission coeﬃcient
varies seasonally, with the timing of the peak deter-
mined by w varying between 0 (=1 January) and 1
(=31 December), and amplitude determined by a
varying between 0 (=constant throughout year) and 1
(=transmission coeﬃcient in the trough being 0). The
seasonality component is assumed to inﬂuence both
groups equally. We allow the transmission term to be
group speciﬁc (i.e. bi) due to variation in infectivity,
and estimate the relative infectiousness of group B to
group A with the parameter r. The basic reproduction
number of the primary infection with group A is
given as:
QA=
bA
(n+m)
: (2)
We are also interested in the role of primary infec-
tions, and so deﬁne the following quantities :
ui(t)=
Pi
Pi+Pji+Yi+Yji
(3)
and
V(t)=
bAPA+bBPB
lA+lB
: (4)
The proportion of prevalent group A infections at
time t that are primary infections (i.e. that are infected
individuals without immunity) is given by uA(t). The
proportion of incident hRSV infections that arise
from primary infections is given by V(t).
Data
Time-series data of hRSV hospitalizations come from
two countries, the United Kingdom and Finland. For
each the data are the weekly number of reported
cases, and the proportion of samples that are group
A. The UK data comprise (i) hRSV hospitalizations
for England & Wales, reported weekly to the
Communicable Disease Surveillance Centre over the
period 1991–2000, and (ii) the annual proportion of
samples taken from Birmingham Heartlands Hospital
(a subset of the total) that are group A between 1989
and 2001 [14]. The Finnish data comprise (i) weekly
hRSV hospitalizations for the Turku region from
1980 to 2001, and (ii) the proportion of monthly
samples taken from the same region that are group A
for the time periods surrounding the major and minor
peaks from 1980 to 2000 [15].
Data scaling and model ﬁtting
Since the weekly incidence data are hospitalizations,
and assumed to be predominantly primary cases, we
use a scaling factor to multiply the predicted primary
incidence of hRSV from the model [(l1+l2)X ] to
compare with observation. The scaling factor, sf, is
given as:
sf=mNcADt, (5)
The components of sf are deﬁned and evaluated as
follows. The inverse of the average life expectancy, m,
is obtained from the life expectancy for each country
[26]. The population size, N, from which the data
originates is 7.5r105 for Finland [27] and 5.6r107 for
England & Wales (ONS, Population Estimates Unit).
The percentage of primary hRSV cases that are hos-
pitalized, c, is taken to be 2.45 [21]. The time between
samples in years, Dt, is 1/52. If the maximum age of
hospitalized children is given by A (between 1 and 2
years) then the scaling factor would be between 4.2
and 8.4 for Finland and 350 and 700 for England &
Wales. Simultaneously, the predicted proportion of
group A incidence [l1/(l1+l2)] was ﬁtted to the pro-
portion of samples of group A.
The model was ﬁtted with parameters including
‘social ’ processes made speciﬁc to the location, and
those including biological processes not location
speciﬁc (referred to as local and global parameters
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respectively in Table 2). The model was ﬁtted using
Berkely Madonna [28], which minimizes the root
mean square deviation (RMSD) of the model predic-
tion from the data using the simplex method [29].
Numerical algorithms were validated in MatLab [30].
We present stable limit cycle results, thus avoiding
the complication of estimating unknown initial con-
ditions since, because the equations are seasonally
forced, the seasonal patterns are repeated.
RESULTS
The parameter estimates are given in Table 2, and the
graphs in Figure 2 show the best ﬁt to the datasets.
Generally, the model reproduces both the epidemic
patterns and the group A dominance time series in
both locations.
The estimates of the global parameters relate
primarily to the natural history of infection in the
individual (Table 2, upper section). Immunity is tem-
porary and lasts on average for approximately 2 years
(i.e. temporary immunity wanes at the rate of 0.51 per
person per year). During the period of immunity,
individuals experience a reduction in the rate of
infection by homologous group virus to 0.36 relative
to uninfected individuals, i.e. a 64% reduction in the
relative per capita incidence. This eﬀect is less pro-
nounced for heterologous re-infection, i.e. an indi-
vidual infected with one group recovers to a partial
immune state in which re-infection incidence with
the heterologous group is reduced to 0.84 (a 16% re-
duction). Hence we estimate the eﬀect of homologous
(or group-speciﬁc) immunity to be four-fold greater
than heterologous (or cross-) immunity. Infected
individuals who have experienced at least one prior
infection are predicted to be less infectious compared
to primary infections by a factor of 0.4, i.e. on average
they are 60% less infectious. There is little asymmetry
in transmissibility between groups: group A is
estimated to be 1.09 times more transmissible than
group B.
The estimates of the local parameters reveal diﬀer-
ences between the two populations (Table 2, lower
section). The seasonally varying transmission
coeﬃcient showed a greater mean and variance in
England & Wales (Fig. 3a, b). The estimates of the
average basic reproduction numbers of primary
group A infection are 2.81 (England & Wales) and
2.46 (Finland). However, the peak in the transmission
coeﬃcient was more similar, estimated to fall
approximately on 5 and 20 December in England &
Wales and Turku respectively.
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Fig. 2. Graphs of the model ﬁt to the time-series data on hRSV hospitalizations for two country locations. The weekly
hospitalizations (shown as crosses) in England & Wales (a) and Turku (b) with the model predictions (solid line). The
proportion of typed samples that were group A in England & Wales (c) and Turku (d ), shown as solid diamonds (with exact
binomial 95% conﬁdence interval where possible) and the corresponding predicted proportion from the model (solid line).
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Fig. 3. Illustrations of the dynamics of the ﬁtted models. Left-hand panels are for England & Wales, right-hand panels for
Turku. In each panel the solid symbols ($) represent the start/end of each year, the peak in transmission occurs just before
them, and the simulations are run over 12 years. (a, b) The seasonal transmission coeﬃcient for group A (bA). The horizontal
line is the mean transmission coeﬃcient. (c, d ) The proportions of the population with primary infections with group A (–––)
and group B (.....), PA and PB respectively. (e, f ) The proportions of the population with immunity to group A only (–––) and
group B only (.....), XA and XB respectively. (g, h) The proportion of group A infections that are primary infections (uA, –––)
and the proportion group B infections that are primary infections (uB, .....). (i, j) The proportion of hRSV infections derived
from primary infections (V).
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The transmission dynamics of the two groups in the
two locations are illustrated in Figure 3. The inter-
actions between seasonal forcing and cross-immunity
create complicated, repeated patterns. In England &
Wales, the combined eﬀect is essentially a limit cycle
with a 6-year period (i.e. the population returns to
its original state every 6 years). However, careful
inspection of Figure 3 (c, e, g) shows that the pattern
generated is actually more complicated, i.e. a 12- or
18-year cycle. The dynamics in Finland are based on a
4-year period. However, these simulations are very
sensitive to speciﬁc parameter values, and a small
change in estimate (well within believable values) can
produce a large eﬀect in dynamic terms.
The eﬀect of the increased amplitude of the trans-
mission coeﬃcient in England & Wales can be seen
particularly in the troughs (between epidemics, in
summer months), where the prevalence of primary
infection reaches two orders of magnitude lower than
in Finland (Fig. 3c, d). The dynamic patterns are most
clearly illustrated by considering the proportions of
the population that are immune to one group only
(Fig. 3e, f ). Note that these individuals can arise
either from infection with one group only or from loss
of immunity following infection with both virus types.
The pattern clearly demonstrates the asymmetry, i.e.
more individuals have been infected with group A
only than group B only in 2–3 years (England &
Wales) and 3–4 years (Turku). It also demonstrates
the competition between groups in that the lines are
highly negatively correlated (increasing XA implies
decreasing XB and vice versa). Simulations with r=1
(not shown) show complete symmetry, thus demon-
strating that a relatively small diﬀerence in the trans-
mission potential can have a large impact.
Generally, prevalent primary infection represents
between 20% and 60% of the total prevalent infec-
tions by group (Fig. 3g, h). Because primary infections
are estimated to be more infectious, they are generally
responsible for between 40% and 80% of all infec-
tions (Fig. 3 i, j). The lowest values tend to occur
during the summer months, i.e. infection from non-
primary infections appears to be responsible for
maintaining infection during non-epidemic periods.
DISCUSSION
The combination of the eﬀects of acquired immunity
and seasonal transmission are able to reproduce
the main features of hRSV epidemiology for two
contrasting time series from two separate locations.
The analysis provides the ﬁrst estimates of the
competitive relationship and cross-immunity between
groups from population level data. Following infec-
tion, individuals gain transient immunity of average
duration 2 years. This immunity is partial in its
eﬃcacy, and greater for homologous challenge (60%)
than heterologous (16%). It is further predicted
that group A hRSV is slightly more transmissible
(8%) than group B.
Seasonal transmission varied between locations in
magnitude (bA), amplitude (a) and phase (w) (timing
of the peak). Alteration of the phase shifts the dynam-
ics along the time axis ; therefore, variation in phase
between locations is not as signiﬁcant as amplitude
and magnitude when considering the dynamics. Dif-
ferent amplitude and magnitude were both necessary
to replicate the dynamic behaviours in the two
locations. The seasonality in transmission (Fig. 3a, b)
does not necessarily represent alterations in contact
rate as is understood for measles [31, 32]. Exploratory
ﬁtting of a single group version of the model to the
incidence data from Turku (not shown here) indicates
that there is a correlation between the phase and
temporary immunity, such that the timing of peak
transmission (i.e. w) in relation to peak incidence
giving abestmodel ﬁt to theobserveddata is dependent
on the rate of waning of immunity. Consequently,
direct, longitudinal estimates of immunity duration
are required to specify the contact rate uniquely.
Model simulations suggest a key role for primary
infections in hRSV transmission (Fig. 3g–j), respon-
sible for, on average, 40–80% of incidence, as a result
of relatively high prevalence (20–40% of prevalent
infection) and infectivity (Table 2). Within the model
structure the origin of these primary infections is
not only individuals who have never previously en-
countered hRSV from birth, but also those who have
lost all ‘memory’ of previous exposure and returned
to a ‘naive’ state. Together they comprise class X
(Fig. 1) and are indistinguishable epidemiologically
(i.e. equally susceptible to infection and equally
infectious when infected), although the latter will have
a much wider age distribution. Suitable data do not
exist by which to validate the model structure. No
explicit account is taken of the higher propensity for
disease in those experiencing a ﬁrst infection follow-
ing birth, though implicitly this is accounted for in the
scaling factor by which the model is ﬁtted to hospital-
ization data. It follows from the above that the model
results should not be regarded as suggesting a cen-
tral role in hRSV epidemiology for young children
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experiencing their ﬁrst ever RSV infection; this
remains an open question for further research.
Although we believe that these conclusions are
robust, it is important to note that the model is merely
one member of a large family of multistrain models
[22], a subset of which may also ﬁt the data equally
well. Therefore, we cannot assume that a model that
provides a ﬁt to the data also provides a description of
the underlying biological mechanism. Previous work
has shown that several mechanistically distinct mod-
els for hRSV can reproduce observed transmission
patterns equally well [21]. We suggest, however, that
temporary intra- and inter-group immunity in some
form would be common to the members of this subset,
but we do not intend our simulations (Fig. 3) to be
regarded as quantitative predictions.
Although not shown here, we attempted to ﬁt the
model with constraints on the parameters’ values. The
dynamics were successfully replicated when heter-
ologous susceptibility was assumed unaltered (she=1)
where the interaction of the groups via altered
duration of secondary infection and the increased
transmissibility of group A compared to group B were
enough to reproduce the dominance patterns. The
dynamics of Finland could be replicated when groups
A and B were assumed equally transmissible (r=1),
but this constraint did not result in the replication of
the dynamics in England & Wales. The complexity
of the model prevented any more formal parameter
estimation.
Perhaps the most robust result is the complexity of
the dynamics illustrated in Fig. 3. Such complexity is
caused by the combination of seasonality and mul-
tiple groups, both of which are logically required and
necessary for providing a ﬁt to the data. One of
the consequences of the complexity is that epidemi-
ological quantities (such as the average age at infec-
tion, or the average time between infections) vary
considerably with time. The expected outcome of
hRSV infection (e.g. age and type of ﬁrst infection)
will also vary for infants by birth season and birth
year (in the epidemic cyclical pattern). We plan to
explore this dynamic complexity.
We have made the simplest possible assumption
regarding virus heterogeneity. The freedom of math-
ematical modelling in the production of ‘n-strain’
models [33] (where n can be any natural number) is
constrained by the two pragmatic concerns of (1) data
abundance/quality and (2) the appropriateness of a
deterministic model. The number of types into which
the samples can be realistically divided, within the
conﬁnes of a longitudinal study of the type described
in ref. [34], is limited and, therefore, limits the
dimension of any useful model. A deterministic model
is appropriate only for large population sizes. If the
model is expressed in deterministic form, as n
increases, the necessary size of a population to be
modelled will also increase for a deterministic struc-
ture to remain appropriate. For example, a 20-strain
model would have in the order of a million compart-
ments and would, therefore, be unsuitable for
England & Wales (population of approximately 53
million). Consequently, future attempts to model
hRSV are likely to be stochastic and to include
speciﬁc mechanisms of viral change and immune
selection [35]. In the current framework, viral diver-
sity is captured in the parameters sho and she and viral
evolution in v, assuming that waning immunity is as a
result of viral change.
Vaccines providing protection against hRSV infec-
tion (or disease) are required and are being developed.
Given the antigenic diversity of the virus, an import-
ant issue is which antigenic components should be
included within a vaccine. Consequently, vaccine
design will beneﬁt from an understanding of the role
the antigenic diversity of the pathogen plays in the
natural history of the disease at both the individual
and population levels. Recent work has indicated that
groups are not linked to severity of infection, but a
clade within group A is [36], although analysis of
samples from The Netherlands found that the G
protein variation did not correlate with disease sev-
erity [37]. Environmental and demographic factors
can be strongly correlated with disease severity [38].
There clearly is potential for the antigenic variation in
hRSV to interact with the transmission dynamics,
although many issues remain to be resolved. For
example, what features of population dynamics pro-
mote antigenic variation, and what eﬀect does anti-
genic variation have on transmission dynamics?
Further, once putative vaccines are developed, math-
ematical models can be used to assess the risk of strain
replacement [33, 39]. There will probably be other
questions such as timing of vaccination (related to
seasonal dynamics), and frequency of vaccination
(related to rate of drift of antigenic types and duration
of immunity).
To obtain a biologically realistic multigroup model
for hRSV the follow-up cohort data generated by
studies such as described in ref. [34] are required to
reﬁne model representation of the natural history of
the infection at the individual level. Such data, which
hRSV group A/B dynamics 287
deﬁne the inﬂuence of prior infection on group and
genotype-speciﬁc immunity, will allow the further
compartmentalization of the virus into types within
the groups and realistically parameterize homologous
and heterologous type immunity.
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